AKBA akebia.com: EV/Sales Multiple

Public company logo of akebia.com (AKBA)

Akebia Therapeutics (AKBA) is restoring its image following FDA approval of key drugs. The price-to-sales multiple trend on GURU.Markets provides a business valuation vector, where 832.15 represents the current metric. The company is developing innovative treatments for renal anemia through R&D investments. Revenues are based on supplies to dialysis centers, whose expenses are covered by insurance programs and Medicare.

Akebia Corp (AKBA): EV/Sales Multiple from 11/23/2025 to 11/22/2026

Akebia Therapeutics Inc - analytical breakdowns and key metrics (AKBA)

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental valuation:Akebia Therapeutics, Inc. AKBA
Original product of Akebia Therapeutics, Inc.

Akebia Therapeutics (AKBA) specializes in anemia therapy for kidney failure, ensuring a stable cash flow through patent protection. This enterprise value-to-revenue multiple compares the total market value of the business with its operating revenues, excluding the impact of debt load. The metric allows for an assessment of real profit generation efficiency relative to capitalization. Investors use this tool to identify overvalued assets. A decrease in values may signal either an undervaluation or a systemic deterioration in profitability.